India, Oct. 30 -- Sun Pharmaceutical Industries Limited (Sun Pharma) announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA).
The approval expands the use of ILUMYA, an IL-23 inhibitor that was initially approved by the FDA in 2018 for treating adults with moderate-to-severe plaque psoriasis. The treatment is administered exclusively by healthcare professionals, offering an additional option for patients who are unable to self-administer medication or require regular in-office care.
The approval is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies, which evaluated...